Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy

J Pharm Pract. 2021 Jun;34(3):343-346. doi: 10.1177/0897190021997001. Epub 2021 Feb 24.

Authors

Muhammad Naveed¹, Shahab Uddin², Muhammad Khalid Khan³, Zakir Khan⁴

Affiliations

¹ Department of Pharmacology and Pharmacotherapy, 37443Faculty of Medicine, University of Szeged, Szeged, Hungary.
² Department of Microbiology, School of Life Sciences, 12426Lanzhou University, Lanzhou, China.
³ Department of Pharmaceutics, Faculty of Pharmacy, 66717Gomal University, DI Khan, Pakistan.
⁴ Tıbbi Farmakoloji Anabilim Dalı, 66757Tıp Fakultesi, Cukurova Universitesi, Sarıcam, Adana, Turkey.

PMID: 33622090
DOI: 10.1177/0897190021997001

No abstract available

Publication types

Letter

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Treatment Outcome

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine